The report analyzes and presents an overview of Digital PCR market worldwide. "Digital polymerase chain reaction (dPCR) is a refined approach used to measure the absolute quantity of DNA molecules in a diluted sample that is partitioned into a large number of chambers or droplets where every chamber contains one (positive) or zero (negative) molecule. Unlike conventional real-time quantitative PCR (qPCR), the dPCR technique involves individual reactions in each chamber, resulting in a more reliable collection of nucleic acid amount. The platform enables researchers to amplify DNA templates for generating amplicons that can be easily detected with sequencing techniques or fluorophores. The dPCR works as an end point to a traditional PCR, and transforms the analog, exponential signals obtained from the device to digital, linear signals."
The report highlights primary benefits of digital PCR (Absolute Measurement of Target Nucleic Acids, Improved Sensitivity and Specificity), and also provides a comparison between Digital PCR and Quantitative PCR. Furthermore, the report briefly discusses the usage of droplet digital PCR technique to develop blood-based biomarkers along several strategic industry activities of major companies worldwide. In addition, 11 companies operating in Digital PCR arena worldwide including Bio-Rad Laboratories Inc., Espira Inc., Fluidigm Corporation, Formulatrix, Genetic ID NA Inc., JN Medsys, LGC Ltd., Life Technologies Corporation, MolecularMD, RainDance Technologies Inc., and TATAA Biocenter AB are profiled.